These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 29074775)

  • 21. The malaria parasite egress protease SUB1 is activated through precise, plasmepsin X-mediated cleavage of the SUB1 prodomain.
    Withers-Martinez C; George R; Maslen S; Jean L; Hackett F; Skehel M; Blackman MJ
    Biochim Biophys Acta Gen Subj; 2024 Sep; 1868(9):130665. PubMed ID: 38969256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploiting Structural Dynamics To Design Open-Flap Inhibitors of Malarial Aspartic Proteases.
    Bobrovs R; Jaudzems K; Jirgensons A
    J Med Chem; 2019 Oct; 62(20):8931-8950. PubMed ID: 31062983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies on plasmepsins I and II from the malarial parasite Plasmodium falciparum and their exploitation as drug targets.
    Moon RP; Bur D; Loetscher H; D'Arcy A; Tyas L; Oefner C; Grueninger-Leitch F; Mona D; Rupp K; Dorn A; Matile H; Certa U; Berry C; Kay J; Ridley RG
    Adv Exp Med Biol; 1998; 436():397-406. PubMed ID: 9561248
    [No Abstract]   [Full Text] [Related]  

  • 24. Novel in vivo active anti-malarials based on a hydroxy-ethyl-amine scaffold.
    Ciana CL; Siegrist R; Aissaoui H; Marx L; Racine S; Meyer S; Binkert C; de Kanter R; Fischli C; Wittlin S; Boss C
    Bioorg Med Chem Lett; 2013 Feb; 23(3):658-62. PubMed ID: 23260352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Substrate Peptidomimetic Inhibitors of P. falciparum Plasmepsin X with Potent Antimalarial Activity.
    Richardson LW; Ashton TD; Dans MG; Nguyen N; Favuzza P; Triglia T; Hodder AN; Ngo A; Jarman KE; Cowman AF; Sleebs BE
    ChemMedChem; 2022 Sep; 17(18):e202200306. PubMed ID: 35906744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasmodium falciparum proteases as new drug targets with special focus on metalloproteases.
    Mahanta PJ; Lhouvum K
    Mol Biochem Parasitol; 2024 Jun; 258():111617. PubMed ID: 38554736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peptidomimetic plasmepsin inhibitors with potent anti-malarial activity and selectivity against cathepsin D.
    Zogota R; Kinena L; Withers-Martinez C; Blackman MJ; Bobrovs R; Pantelejevs T; Kanepe-Lapsa I; Ozola V; Jaudzems K; Suna E; Jirgensons A
    Eur J Med Chem; 2019 Feb; 163():344-352. PubMed ID: 30529637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins.
    Jiang S; Prigge ST; Wei L; Gao Ye ; Hudson TH; Gerena L; Dame JB; Kyle DE
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2577-84. PubMed ID: 11502532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of
    Lowe MA; Cardenas A; Valentin JP; Zhu Z; Abendroth J; Castro JL; Class R; Delaunois A; Fleurance R; Gerets H; Gryshkova V; King L; Lorimer DD; MacCoss M; Rowley JH; Rosseels ML; Royer L; Taylor RD; Wong M; Zaccheo O; Chavan VP; Ghule GA; Tapkir BK; Burrows JN; Duffey M; Rottmann M; Wittlin S; Angulo-Barturen I; Jiménez-Díaz MB; Striepen J; Fairhurst KJ; Yeo T; Fidock DA; Cowman AF; Favuzza P; Crespo-Fernandez B; Gamo FJ; Goldberg DE; Soldati-Favre D; Laleu B; de Haro T
    J Med Chem; 2022 Oct; 65(20):14121-14143. PubMed ID: 36216349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis, biological evaluation, and modeling studies of inhibitors aimed at the malarial proteases plasmepsins I and II.
    Muthas D; Nöteberg D; Sabnis YA; Hamelink E; Vrang L; Samuelsson B; Karlén A; Hallberg A
    Bioorg Med Chem; 2005 Sep; 13(18):5371-90. PubMed ID: 16054370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of plasmepsin inhibitor by focusing on similar structural feature with chloroquine to avoid drug-resistant mechanism of Plasmodium falciparum.
    Miura T; Hidaka K; Azai Y; Kashimoto K; Kawasaki Y; Chen SE; de Freitas RF; Freire E; Kiso Y
    Bioorg Med Chem Lett; 2014 Apr; 24(7):1698-701. PubMed ID: 24631188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, antimalarial evaluation and molecular modeling studies of hydroxyethylpiperazines, potential aspartyl protease inhibitors, part 2.
    Cunico W; Gomes CR; Facchinetti V; Moreth M; Penido C; Henriques MG; Varotti FP; Krettli LG; Krettli AU; da Silva FS; Caffarena ER; de Magalhães CS
    Eur J Med Chem; 2009 Sep; 44(9):3816-20. PubMed ID: 19403210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs.
    Herman JD; Pepper LR; Cortese JF; Estiu G; Galinsky K; Zuzarte-Luis V; Derbyshire ER; Ribacke U; Lukens AK; Santos SA; Patel V; Clish CB; Sullivan WJ; Zhou H; Bopp SE; Schimmel P; Lindquist S; Clardy J; Mota MM; Keller TL; Whitman M; Wiest O; Wirth DF; Mazitschek R
    Sci Transl Med; 2015 May; 7(288):288ra77. PubMed ID: 25995223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function.
    Bonilla JA; Bonilla TD; Yowell CA; Fujioka H; Dame JB
    Mol Microbiol; 2007 Jul; 65(1):64-75. PubMed ID: 17581121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitors of the Plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agents.
    Boss C; Richard-Bildstein S; Weller T; Fischli W; Meyer S; Binkert C
    Curr Med Chem; 2003 Jun; 10(11):883-907. PubMed ID: 12678679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Helicases - feasible antimalarial drug target for Plasmodium falciparum.
    Tuteja R
    FEBS J; 2007 Sep; 274(18):4699-704. PubMed ID: 17824956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. That was then but this is now: malaria research in the time of an eradication agenda.
    Kappe SH; Vaughan AM; Boddey JA; Cowman AF
    Science; 2010 May; 328(5980):862-6. PubMed ID: 20466924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimalarial activity of HIV-1 protease inhibitor in chromone series.
    Lerdsirisuk P; Maicheen C; Ungwitayatorn J
    Bioorg Chem; 2014 Dec; 57():142-147. PubMed ID: 25462990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteases of malaria parasites: new targets for chemotherapy.
    Rosenthal PJ
    Emerg Infect Dis; 1998; 4(1):49-57. PubMed ID: 9452398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine.
    Banerjee R; Liu J; Beatty W; Pelosof L; Klemba M; Goldberg DE
    Proc Natl Acad Sci U S A; 2002 Jan; 99(2):990-5. PubMed ID: 11782538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.